Physician profile
Amelia B Tower
NPI 1003257957
$557.87
in general payments reported to CMS, 2019-2025
11 companies · $36.91 in 2025
The $36.91 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.55 · 2021: $24.23 · 2022: $172 · 2023: $113 · 2024: $163 · 2025: $36.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $202.93 | 2023-2024 | Endurant Iis, Plasmablade(Tm) |
| Ethicon US, LLC | $76.49 | 2022-2023 | Echelon Flex, Enseal |
| Intuitive Surgical, INC. | $65.09 | 2022 | |
| Bard Peripheral Vascular, INC. | $61.37 | 2021-2022 | |
| Elucent Medical | $37.90 | 2022-2025 | |
| Kerecis Limited | $30.96 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Celgene Corporation | $19.53 | 2020 | |
| Tactile Systems Technology INC | $18.40 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.87 | 2020 | |
| Boston Scientific Corporation | $16.18 | 2025 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Tower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.